Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs

References

• Kohler BA, Sherman RL, Howladeret N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 2015;107:1-26
   Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer Treatment and Survivorship Statistics, 2012. CA Cancer J Clin 2012;62:220-241
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717
   PubMed Web of Science ®Google Scholar
• Saurabh J. The mammogram debate: how much should be spent to save one life? Medscape Oncol 2016;February 25th. Available from http://www.medscape.com/viewarticle/859234
   Google Scholar
• Siu AL, US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:279-96
   PubMed Web of Science ®Google Scholar
• Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010;7:18-27
   PubMed Web of Science ®Google Scholar
• Tabár L, Vitak B, Chen TH, et al. Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260:658-63
   PubMed Web of Science ®Google Scholar
• Miller AB, Wall C, Baines CJ, et al. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 2014;348:g366
   PubMed Web of Science ®Google Scholar
• Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to “save lives”—and what we can do about it. BMJ 2016;352:h6080
   PubMed Web of Science ®Google Scholar
• Lauby‐Secretan B, Scoccianti C, Loomis D, et al, for the International Agency for Research on Cancer Handbook Working Group. Breast-cancer screening—Viewpoint of the IARC Working Group. N Engl J Med 2015;372:2353-2358
   PubMed Web of Science ®Google Scholar
• Biller-Andorno N. A view from the Swiss medical board. N Engl J Med 2014;370:1965-7
   PubMed Web of Science ®Google Scholar
• Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005
   PubMed Web of Science ®Google Scholar
• Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer. JAMA 2013;310:797-8
   PubMed Web of Science ®Google Scholar
• Helvie MA, Chang JT, Hendrick RE, et al. Reduction in late-stage breast cancer incidence in the mammography era: implications for overdiagnosis of invasive cancer. Cancer 2014;120:2649-56
   PubMed Web of Science ®Google Scholar
• Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 2014;311:1327-35
   PubMed Web of Science ®Google Scholar
• Ong MS, Mandl KD. National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Aff (Millwood) 2015;34:576-83
   PubMed Web of Science ®Google Scholar
• Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-86
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC, Jørgensen KJ, Donzelli A, et al. Comments to: The benefits and harms of breast cancer screening Lancet 2013;381:799-800
   PubMed Web of Science ®Google Scholar
• BreastScreen Australia Evaluation Taskforce. BreastScreen Australia Evaluation. Evaluation final report. Canberra: Australian Government Department of Health and Ageing; 2009. Report No.: Screening Monograph No.1/2009. http://www.health.gov.au/internet/screening/publishing.nsf/content/8463830B90E5BDF5CA25. Last accessed February 17, 2016
   Google Scholar
• Birnbaum J, Gadi VK, Markowitz E, et al. The effect of treatment advances on the mortality results of breast cancer screening trials: a microsimulation model. Ann Intern Med 2016;164:236-43
   PubMed Web of Science ®Google Scholar
• Berry DA, Cronin KA, Plevritis SK, et al., for the Cancer Intervention and Surveillance Modeling Network (CISNET). Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92
   PubMed Web of Science ®Google Scholar
• Puliti D, Miccinesi G, Manneschi G, et al. Does an organised screening programme reduce the inequalities in breast cancer survival? Ann Oncol 2012;23:319-23
   PubMed Web of Science ®Google Scholar
• O’Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 2006;30:1491-1501
   PubMed Web of Science ®Google Scholar
• Simon K. Colorectal cancer development and advances in screening. Clin Interv Aging 2016;11:967-76
   PubMed Web of Science ®Google Scholar
• Vanchieri C. When will the US flinch at cancer drug prices? J Natl Cancer Inst 2005;97:9
   Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000;9:235-51
   PubMed Web of Science ®Google Scholar
• https://knoema.com/sijweyg/gdp-per-capita-ranking-2015-data-and-charts. Accessed July 17, 2016
   Google Scholar
• Hui-Chu L, Hsiao-Wei C, Tzeon-Jye C, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive early breast cancer in Taiwan. J Med Econ19:923-927
   PubMed Web of Science ®Google Scholar
• Wei Ching L, Mohd Roslan H, Kong Leong Y, et al. Economic analysis of intravenous vs subcutaneously administered trastuzumab for the treatment of HER2+ early breast cancer in Malaysia. Adv Breast Cancer Res 2016;5:1-13
   Google Scholar
• de Lima Lopes Jr G. Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore. BMC Cancer 2011;11:178
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica 2013;33:411-17
   PubMed Web of Science ®Google Scholar
• Mylonas C, Kourlaba G, Fountzilas G, et al. Cost-minimization analysis of trastuzumab intravenous versus trastuzumab subcutaneous for the treatment of patients with HER2+ early breast cancer and metastatic breast cancer in Greece. Value Health 2014;17:A640-1
   Google Scholar
• Barry AM, Casselman B. 33 Million Americans still don’t have health insurance. Here’s who they are. Report on public health, food and culture for FiveThirtyEight. Sep 28, 2015. Available from https://fivethirtyeight.com/features/33-million-americans-still-dont-have-health-insurance/; accessed on Feb 17th, 2016
   Google Scholar
• de Souza JA, Hunt B, Asirwa FC, et al. Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. J Clin Oncol 2015;34:6-13
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer (USA). J Clin Oncol. 2016;34:980-6
   PubMed Web of Science ®Google Scholar
• Huntington SF, Weiss BM, Vogl DT, et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Oncol 2015;2:e408-e416
   Google Scholar
• Banegas MP, Guy GP Jr, de Moor JS, et al. Cost of cancer care for working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff 2016;35:154-61
   Web of Science ®Google Scholar
• Bach PB. New math on drug cost-effectiveness. N Engl J Med 2015;373:1797
   PubMed Web of Science ®Google Scholar
• Cherny N, Sullivan R, Torode J et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.Ann Oncol. 2016;27:1423-43
   Google Scholar
• Allemani C, Storm H, Voogd AC, et al. Variation in ‘standard care’ for breast cancer across Europe: A EUROCARE-3 high resolution study. Eur J Cancer. 2010;46:1528-36
   PubMed Web of Science ®Google Scholar
• GoodRX, online sale of drugs. http://www.goodrx.com/palbociclib. Accessed July 17, 2016
   Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med 2015;373:209-19
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turne NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425-39
   PubMed Web of Science ®Google Scholar
• IBRANCE. https://www.ibrance.com/getting-ibrance. Accessed July 17, 2016
   Google Scholar
• Matter-Walstra K, Schwenkglenks M, Brauchli P, et al. A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer. J Clin Oncol 2016;34(suppl):abstr 567
   Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738-48
   PubMed Web of Science ®Google Scholar
• Gatta G, Trama A, Capocaccia R. Variations in cancer survival and patterns of care across Europe: roles of wealth and health-care organization. JNCI Monographs 2013;46:79-87
   Google Scholar
• Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12:933-80
   PubMed Web of Science ®Google Scholar
• Ruff P, Al-Sukhun P, Blanchard C, et al. Access to cancer therapeutics in low- and middle-income countries. ASCO Educational Book. asco.org/edbook; 2016;58:65
   Google Scholar
• Saltz LB. The value of considering cost, and the cost of not considering value. J Clin Oncol 2016;34:659-60
   PubMed Web of Science ®Google Scholar
• Mustacchi G. L'Italia sta per affrontare il bivio costi-opportunitá e il rebus sostenibilità: la decisione sia di chi governa. Il Sole 24 Ore. Health Suppl to n49; Dec 20th 2005
   Google Scholar